NIKKEI 225
38,640.37 +7.35 (+0.02%) HANG SENG
18,004.89 -330.43 (-1.80%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.70 +7.70 (+0.33%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,966.51 -626.05 (-1.21%)
Lyell Immunopharma, Inc. (LYEL)
After hours:
- GlobeNewswire
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 pm ET. A live webcast of the presentation can be accessed through the Investors section of the Company's w
- GlobeNewswire
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the BofA Securities 2024 Health Care Conference on Tuesday, May 14 at 8:40 am PT. A live webcast of the presentation can be accessed through the Investors section of the Company's website at ww
- Simply Wall St.
Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
Lyell Immunopharma ( NASDAQ:LYEL ) First Quarter 2024 Results Key Financial Results Net loss: US$60.7m (loss narrowed...
